F S&P 500
5,119.25 +12.75 (+0.25%) F Dow Jones
38,735.00 +9.00 (+0.02%) F Nasdaq
17,727.75 +121.00 (+0.69%) E-mini Russell 2000 Index Futur
2,012.40 -2.50 (-0.12%) Petróleo
83.44 +0.08 (+0.10%) Oro
2,336.80 -5.30 (-0.23%)
Boundless Bio, Inc. (BOLD)
Boundless Bio, Inc.
9880 Campus Point Drive
Suite 120
San Diego, CA 92121
United States
(858) 766-9912
https://boundlessbio.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 72
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Jonathan E. Lim M.D. | Co-Founder & Independent Chairman | N/D | N/D | 1972 |
| Mr. Zachary Hornby | CEO, President & Director | 721.05k | N/D | 1979 |
| Dr. Christian Hassig Ph.D. | Chief Scientific Officer | 563.55k | N/D | 1973 |
| Dr. Klaus W. Wagner M.D., Ph.D. | Chief Medical Officer | 633.08k | N/D | 1973 |
| Ms. Jamilu E. Rubin | Chief Financial Officer | N/D | N/D | 1965 |
| Ms. Jessica Oien J.D. | Chief Legal Officer & Corporate Secretary | N/D | N/D | 1972 |
| Mr. Neil Abdollahian M.B.A., M.S. | Chief Business Officer | N/D | N/D | 1973 |
| Mr. Anthony Pinkerton Ph.D. | Senior Vice President of Drug Discovery | N/D | N/D | N/D |
| Ms. Meredith Wesley | Senior Vice President of Talent & Culture | N/D | N/D | N/D |
| Dr. Shailaja Kasibhatla Ph.D. | Senior Vice President of Discovery & Translational Development | N/D | N/D | N/D |
Descripción
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.
Gestión corporativa
La calificación ISS Governance QuickScore de Boundless Bio, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
